Neuromonitoring for Brain-Injured Patients

The system has been cleared by the U.S. Food and Drug Administration (FDA).

Called NeuroSensor, the system is easy to use, allowing clinicians to obtain simultaneous measurements of a patient's CBF and ICP through the use of a single catheter inserted through a low-profile bolt. The system provides relevant measurements for a surgeon on a real-time basis, allowing for continuous qualitative monitoring in patients at risk of cerebral ischemia and for the direct monitoring of ICP in intraparenchymal applications following injury or neurosurgical procedures. The sensor measures CBF using laser Doppler flowmetry technology, while ICP is measured by a microelectromechanical system (MEMS). By detecting the conditions that lead to increased ICP, such as certain changes in CBF, further injury to the brain may be prevented or limited.

"Our goal is to provide online and real-time multimodality monitoring as the standard of care,” noted Deborah Leonetti, senior vice president of marketing for Integra Lifesciences Holdings Corp. (Plainsboro, NJ, USA; www.integra-ls.com), which developed the neuromonitoring system. "We are very proud to offer this cutting-edge technology for the treatment and care of patients with neurotrauma and cerebrovascular disease.”




Related Links:
Integra